Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Neurol Sci ; 285(1-2): 159-71, 2009 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-19631348

RESUMEN

Dystrophin-deficient muscle exhibits substantial increases in nuclear NF-kappaB activation. To examine potential mechanisms for this enhanced activation, the present study employs conventional Western blot techniques to provide the first determination of the relative expression of NF-kappaB signaling molecules in adult nondystrophic and dystrophic (mdx) skeletal muscle. The results indicate that dystrophic muscle is characterized by increases in the whole cell expression of IkappaB-alpha, p65, p50, RelB, p100, p52, IKK, and TRAF-3. The proportion of phosphorylated IkappaB-alpha, p65, NIK, and IKKbeta, and the level of cytosolic IkappaB-alpha, were also increased in the mdx diaphragm. Proteasomal inhibition using MG-132 increased the proportion of phosphorylated IkappaB-alpha in nondystrophic diaphragm, but did not significantly increase this proportion in the mdx diaphragm. This result suggests that phosphorylated IkappaB-alpha accumulates in dystrophic cytosol because the rate of IkappaB-alpha degradation is lower than the effective rate of IkappaB-alpha synthesis and phosphorylation. Dystrophic increases in SUMO-1 (small ubiquitin modifier-1) protein and in Akt activation were also observed. The results indicate that increases in nuclear p65 activation in dystrophic muscle are not produced solely by increases in the activity of IkappaB-alpha kinase (IKK), but are due primarily to increases in the expression of p65 and other NF-kappaB signaling components.


Asunto(s)
Núcleo Celular/metabolismo , Citosol/metabolismo , Diafragma/metabolismo , Quinasa I-kappa B/metabolismo , Músculo Esquelético/metabolismo , Distrofias Musculares/metabolismo , Factor de Transcripción ReIA/metabolismo , Animales , Femenino , Cinética , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos mdx , Fosforilación , Proteínas Proto-Oncogénicas c-akt/metabolismo , Proteína SUMO-1/metabolismo
2.
Neuromuscul Disord ; 19(2): 131-9, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19054675

RESUMEN

The whole body tension (WBT) method was used to evaluate the hypothesis that long term treatment with NF-kappaB inhibitors improves the total forward pulling tension exerted by the limb musculature of the mdx mouse. Mdx mice exhibited significantly reduced WBT values and more profound weakening during the course of generating multiple forward pulling movements than age-matched nondystrophic mice. Long term treatment with the NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC) did not significantly reduce nuclear p65 activation in the costal diaphragm, but increased WBT by 12% in mature (12 month) mice. Daily treatment (30 days) of 1 month old mdx mice with the inhibitor ursodeoxycholic acid (UDCA) reduced costal diaphragm nuclear p65 activation by 40% and increased WBT by 21%. These results indicate that treatment with NF-kappaB inhibitors improves WBT in the mdx mouse and further establishes the utility of the WBT procedure in assessing therapeutic efficacy.


Asunto(s)
Tono Muscular/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Distrofia Muscular de Duchenne/tratamiento farmacológico , FN-kappa B/antagonistas & inhibidores , Pirrolidinas/farmacología , Tiocarbamatos/farmacología , Animales , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Colagogos y Coleréticos/farmacología , Modelos Animales de Enfermedad , Femenino , Masculino , Ratones , Ratones Endogámicos mdx , Fuerza Muscular/efectos de los fármacos , Fuerza Muscular/fisiología , Ejercicios de Estiramiento Muscular/efectos adversos , Tono Muscular/fisiología , Debilidad Muscular/tratamiento farmacológico , Debilidad Muscular/metabolismo , Debilidad Muscular/fisiopatología , Músculo Esquelético/metabolismo , Músculo Esquelético/fisiopatología , Distrofia Muscular de Duchenne/metabolismo , Distrofia Muscular de Duchenne/fisiopatología , FN-kappa B/metabolismo , Pirrolidinas/uso terapéutico , Recuperación de la Función/efectos de los fármacos , Recuperación de la Función/fisiología , Tiocarbamatos/uso terapéutico , Factor de Transcripción ReIA/antagonistas & inhibidores , Factor de Transcripción ReIA/metabolismo , Resultado del Tratamiento , Ácido Ursodesoxicólico/farmacología , Ácido Ursodesoxicólico/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA